Drug Trial Radar · NCT02900664
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Last checked: Nov 20, 2026Latest source record: Mar 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
283
Actual
Start
Aug 23, 2016
Primary completion
Mar 17, 2021
Study completion Mar 17, 2021
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.
Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Interventions
PDR001Biological
Powder for solution for infusion
ACZ885Biological
Solution for injection
CJM112Biological
Solution for infusion
TMT212Drug
Tablets
EGF816Drug
Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safetyTime frame: Throughout the study at every visit, an average of 1 year
- Changes between baseline and post-baseline laboratory parameters and vital signs.Time frame: Baseline and throughout the study at every visit, an average of 1 year
- Incidence of dose limiting toxicities (DLTs) of treatment (Escalation only)Time frame: During the first two cycles; Cycle = 28 days
- Frequency of dose interruptionsTime frame: Throughout the study at every visit, an average of 1 year
- Dose intensitiesTime frame: Throughout the study at every visit, an average of 1 year
- Severity of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safetyTime frame: Throughout the study at every visit, an average of 1 year
- Frequency of dose reductionsTime frame: Throughout the study at every visit, an average of 1 year
Locations
23 sites in 9 countries. Site status is shown where the registry gives one.
Sidney Kimmel Comprehensive Cancer Center SC-3
Baltimore, Maryland
Dana Farber Cancer Center
Boston, Massachusetts
Sarah Cannon Research Institute
Nashville, Tennessee
University of Texas MD Anderson Cancer Center
Houston, Texas
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Wilrijk, Belgium
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Tel Aviv, Israel
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Rozzano, MI, Italy
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
L'Hospitalet de Llobregat, Catalonia, Spain
Novartis Investigative Site
Tainan, Taiwan
Novartis Investigative Site
Taoyuan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.